Frost & Sullivan

Companies Frost & Sullivan

News Frost & Sullivan

• Frost & Sullivan: Opportunities for electronics manufacturing services in medical industry increasing

  Original equipment manufacturers (OEMs) are increasingly turning to electronics manufacturing service (EMS) providers to better handle the escalating volumes of electronic content in the medical industry. With opportunities for high-level product assembly and complete build projects expected to incr more

• Frost & Sullivan commends Merck Serono for its excellence in product differentiation

  Merck Serono announced that based on its recent analysis of the human growth hormones (HGH) market, Frost & Sullivan recognises Merck Serono with the 2013 Europe Product Differentiation Excellence Award. “Merck Serono is lauded for its cutting-edge drug delivery devices - easypod® and cool.click®2 – more

• Emphasis on X-ray quality spurs adoption of radiography, finds Frost & Sullivan

  The need to improve the efficiency and quality of X-ray examinations will drive healthcare facilities across Europe to install computed radiography (CR) and digital radiography (DR) systems. The emergence of retrofit systems based on flat panel technology has popularised DR systems, and will sustain more

White papers Frost & Sullivan

• Outsourcing in Clinical Research - The Indian Perspective
  

  New pharmaceutical strategies pursue increased Research and Development (R&D) investments ranging 15-20% in contrast to late 80's period where classical model across was 10%. The annual budget allocation spent with clinical research organizations (CRO) is approximately $12 billion in an attempt to increase throughput, which has predominantly benefited CRO's who have seen their turnover boost growth of 20-30% year on year. more

• Outsourcing to India and China: Cultural diffculties with the perception of costs
  

  Aparna Singh (AS), Program Manager for the Chemicals Materials and Foods team at Frost & Sullivan India, recently caught up with Mr. Steve Fishwick (SF), Projects Group Director, AstraZeneca at the Frost & Sullivan's Global Life Sciences Summit 2006 at Goa, India. He was one of the key speakers at this premium summit. more

• Alliances in Drug Discovery - The Chemical Element
  

  Alliances have evolved into a critical cornerstone of R&D strategy in the global pharmaceutical industry. No other industry has been leveraging this business model as successfully as the global pharmaceutical industry in its drive for innovation and success. Over three thousand deals amounting to a cumulative payout of US$ 17bn have been signed by pharmaceutical and biotech players in a span of two decades. In the past five years the industry's mania to develop new generation blockbuster drugs has taken on a new sense of urgency as 64% of the alliance value was inked and paid out during the period. more

Websites Frost & Sullivan